Loading...
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study.
Van Cutsem, E Yoshino, T Lenz, H Lonardi, S Falcone, A Limón, M Saunders, Mark P Sobrero, A Park, Y Ferreiro, R
Van Cutsem, E
Yoshino, T
Lenz, H
Lonardi, S
Falcone, A
Limón, M
Saunders, Mark P
Sobrero, A
Park, Y
Ferreiro, R
Citations
Altmetric:
Abstract
Angiogenesis is critical to colorectal cancer (CRC) growth and metastasis. Phase I/II studies have demonstrated the efficacy of nintedanib, a triple angiokinase inhibitor, in patients with metastatic CRC. This global, randomized, phase III study investigated the efficacy and safety of nintedanib in patients with refractory CRC after failure of standard therapies.
Description
Date
2018-07-13
Publisher
Collections
Files
Keywords
Type
Article
Citation
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study. 2018, Ann Oncol